Biotie Therapies - Company Announcement

Peter Fellner nominated to be elected to Biotie's Board of Directors

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE  September 28, 2009
at 9.00 a.m.

Peter Fellner nominated to be elected to Biotie's Board of Directors

The Board of Directors proposes for the Extraordinary General Meeting
on October 29, 2009 on the basis of the recommendation of the Board's
Nomination and Remuneration Committee that the number of members of
the Board of Directors would be eight (8) and that Dr. Peter Fellner
would be elected as a new member of the Board of Directors for the
term expiring at the end of the following Annual General Meeting.

Dr. Fellner, 65, currently serves as Chairman of Consort Medical Plc,
Chairman of Vernalis Plc and Chairman of Astex Therapeutics Ltd.
Previously he served as CEO of Celltech Group plc from 1990 to 2003,
and then as its Chairman until 2004. Prior to this he was CEO of
Roche UK from 1986 to 1990. He has also served as a director of
several other public companies.

Dr. Fellner has given his consent to Board service. He is independent
of the company and independent of significant shareholders of the
company.

This proposal is included in the invitation to the Extraordinary
General Meeting, dated 28 September, 2009.


Turku, September 28, 2009

Biotie Therapies Corp.


Timo Veromaa
President and CEO

For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central
nervous system and inflammatory diseases. It has a broad range of
innovative small molecule and biological drug candidates at different
stages of clinical and pre-clinical development. Biotie's products
address diseases with high unmet medical need and significant market
potential, including addiction and psychotic disorders, rheumatoid
arthritis, psoriasis and chronic obstructive pulmonary disease
(COPD). The most advanced product, nalmefene for alcohol dependence,
is currently in phase III clinical development by licensing partner
H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through
existing alliances with top-tier global pharmaceutical companies such
as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland
and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.